F331-dTAG-MYC cells were injected intra-tibially into C57BL/6 mice, and upon detection of palpable tumor, mice were randomized to receive treatment either with dTAG-v1 or with vehicle control for 2 weeks intravenously via retro-orbital injection. This evidence concerns the gene MYC and neoplasm.